Alan Barge, MD

Dr. Barge is trained in medicine at Oxford and London, and specialized in hematology and oncology, completed research and clinical fellowships in Seattle in 1990. After a decade of drug development experience, he joined AstraZeneca, where he established a team responsible for early phase oncology drug development and responsible for development, and registration of Iressa® (gefitinib) in Asia, and Europe, in molecularly defined subsets of NSCLC. He was subsequently appointed as VP of Clinical and Head of Oncology and Infection, responsible for building and managing a large development group, and the execution of AstraZeneca’s oncology portfolio globally. Subsequently, he co-founded ASLAN Pharmaceuticals and Carrick Therapeutics, focused on the development of oncology assets. Currently, he is a partner in Delvin ventures. He brings significant cancer therapeutic development and network in venture capital world to Onconox.